<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340233</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#17-000695</org_study_id>
    <secondary_id>1R01HL131823-01A1</secondary_id>
    <nct_id>NCT03340233</nct_id>
  </id_info>
  <brief_title>Understanding the Mechanisms of Diastolic Dysfunction</brief_title>
  <official_title>A New Framework for Understanding the Mechanism of Diastolic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is a clinical syndrome marked by breathlessness, even at low levels of&#xD;
      exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people&#xD;
      in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the&#xD;
      heart pumps enough blood to the body, but patients still have terrible symptoms. It is&#xD;
      estimated to account for about 50% of all heart failure cases. Experts agree that impaired&#xD;
      filling of the heart, perhaps due to &quot;stiffness&quot; of the heart muscle itself, critically&#xD;
      underlies HFpEF. There is currently no clinical technique for measuring heart muscle&#xD;
      (myocardial) stiffness; the very definition of &quot;myocardial stiffness&quot; remains poorly&#xD;
      established. Consequently, the ability to study the mechanisms that underlie HFpEF is&#xD;
      virtually non-existent, and limited treatment options will persist without significant&#xD;
      advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS)&#xD;
      framework that couples patient-specific clinical MRI and heart pressure data in a&#xD;
      computational model of the heart to diagnose changes in myocardial stiffness. The central&#xD;
      hypothesis is that the new EMS framework for understanding the mechanisms of diastolic&#xD;
      dysfunction in HFpEF will be more sensitive and outperform currently available approaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has three aims. The first aim of the project is to refine MRI techniques using&#xD;
      &quot;free-breathing&quot; versus &quot;breath-holding&quot; measurements. Twenty-five normal volunteers will&#xD;
      undergo MRI to refine &quot;free-breathing&quot; cardiac imaging and enable construction of&#xD;
      patient-specific computer models of the heart. The second aim of the project is to validate&#xD;
      and test the myocardial stiffness evaluation framework derived through the first objective in&#xD;
      human subjects. Twenty-five normal volunteers will undergo MRI and the data from these images&#xD;
      will be compared to specially constructed 3D printed models of the heart, enabling refinement&#xD;
      of the EMS framework to separate structural stiffness from material stiffness. The third aim&#xD;
      of the project is to measure changes in myocardial stiffness in patients with HFpEF.&#xD;
      Thirty-three subjects with current diagnostic criteria for HFpEF will be evaluated at&#xD;
      baseline and at six months to evaluate myocardial stiffness and cardiac MRI biomarkers.&#xD;
      Specifically, this aim will establish the diagnostic sensitivity of the EMS framework with&#xD;
      comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic&#xD;
      insight to one critical underlying cause of HFpEF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The PI left the institution and closed the study prior to enrolling any participants&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The sensitivity of the EMS framework with comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic insight to one critical underlying cause of HFpEF.</measure>
    <time_frame>Five years</time_frame>
    <description>Assess the diagnostic sensitivity of MRI method by analyzing baseline and six month longitudinal characteristics in myocardial stiffness measured in patients with HFpEF</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI (cardiac) off-label use gadolinium contrast (IND exempt)</intervention_name>
    <description>Clinical MRI</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI (cardiac)</intervention_name>
    <description>MRI without contrast</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy volunteers&#xD;
&#xD;
        1. Healthy adults&#xD;
&#xD;
        Patients with Heart Failure with Preserved Ejection Fraction&#xD;
&#xD;
          1. Patient scheduled for catheterization at UCLA Medical Center&#xD;
&#xD;
          2. Ejection fraction &gt;/= 50%&#xD;
&#xD;
          3. Signs and symptoms of heart failure&#xD;
&#xD;
          4. Excluded other potential non-cardiac etiologies of heart failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy volunteers&#xD;
&#xD;
          1. Known medical condition that impacts heart health&#xD;
&#xD;
          2. Contraindications to MRI (e.g., pacemaker/ICD, or claustrophobia)&#xD;
&#xD;
        Patients with Heart Failure with Preserved Ejection Fraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to MRI (e.g., pacemaker/ICD, or claustrophobia)&#xD;
&#xD;
          2. Prior MI or history of PCI/CABG&#xD;
&#xD;
          3. Worse than mild valvular disease&#xD;
&#xD;
          4. Any indication for ICD implantation&#xD;
&#xD;
          5. Contraindication to MRI contrast agents or eGRF &lt;30 ml/min/1.73m2 or MRI exams (e.g.,&#xD;
             pacemaker/ICD or claustrophobia).&#xD;
&#xD;
          6. Atrial fibrillation or unstable cardiac rhythm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Ennis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Daniel Ennis, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>diastolic dysfunction</keyword>
  <keyword>mechanism</keyword>
  <keyword>MRI magnetic resonance imaging</keyword>
  <keyword>ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

